Scopolamine for Vertigo Management

Introduction to Scopolamine Use

The American Academy of Otolaryngology-Head and Neck Surgery recommends that scopolamine should only be used for short-term management of vertigo during acute Ménière's disease attacks, not as a long-term treatment 1, 2, 3
The American Academy of Otolaryngology-Head and Neck Surgery suggests that transdermal scopolamine is the most common formulation, primarily created to prevent motion sickness rather than treat other forms of vertigo 1, 2, 3

There is insufficient evidence demonstrating the relative efficacy of scopolamine compared to other vestibular suppressants for vertigo management 1, 2, 3
For Ménière's disease specifically, a limited course of vestibular suppressants like scopolamine is recommended only during acute attacks 4

Scopolamine can cause significant adverse effects including blurred vision, dry mouth, dilated pupils, urinary retention, and sedation 1, 2, 3
Due to its side effect profile and potential for significant toxicity and withdrawal effects when used for more than several days, scopolamine is not commonly prescribed for acute vertigo control associated with Ménière's disease 1, 2, 3
Prolonged use of vestibular suppressants like scopolamine can interfere with central compensation in peripheral vestibular conditions, potentially delaying recovery 4
Anticholinergic medications are a significant independent risk factor for falls, especially in elderly patients 4

For most forms of vertigo, other treatment options are preferred over scopolamine, such as meclizine, which is the most commonly used antihistamine for peripheral vertigo and should be used primarily as-needed rather than on a scheduled basis 4
For severe nausea/vomiting associated with vertigo, prochlorperazine may be considered for short-term management 4, 5
For anxiety components of vertigo, short-term benzodiazepines may be appropriate 4
Lifestyle modifications are recommended for managing vertigo symptoms, including limiting salt/sodium intake, avoiding excessive caffeine, alcohol, and nicotine, maintaining adequate hydration, regular exercise, and sufficient sleep, and managing stress appropriately 4

Patients should be reassessed within 1 month after initial treatment to document resolution or persistence of symptoms 4